Free Trial

Bio-Rad Laboratories (BIO) Stock Price, News & Analysis

-1.59 (-0.54%)
(As of 05/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
237,864 shs
Average Volume
206,482 shs
Market Capitalization
$8.28 billion
P/E Ratio
Dividend Yield
Price Target

Bio-Rad Laboratories MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
58.8% Upside
$461.00 Price Target
Short Interest
3.73% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.92mentions of Bio-Rad Laboratories in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$1.01 M Sold Last Quarter
Proj. Earnings Growth
From $10.41 to $11.46 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.67 out of 5 stars

Medical Sector

69th out of 916 stocks

Analytical Instruments Industry

2nd out of 28 stocks

BIO stock logo

About Bio-Rad Laboratories Stock (NYSE:BIO)

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

BIO Stock Price History

BIO Stock News Headlines

Precision BioSciences earnings: here's what Wall Street expects
Q1 2024 Bio Rad Laboratories Inc Earnings Call
25 Countries with Highest Malaria Death Rates
BIO Apr 2024 340.000 call
See More Headlines
Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Analytical instruments
Life Sciences Tools & Services
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$2.67 billion
Cash Flow
$12.14 per share
Book Value
$317.31 per share


Free Float
Market Cap
$8.28 billion

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

BIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Bio-Rad Laboratories stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BIO shares.
View BIO analyst ratings
or view top-rated stocks.

What is Bio-Rad Laboratories' stock price target for 2024?

5 equities research analysts have issued twelve-month price objectives for Bio-Rad Laboratories' stock. Their BIO share price targets range from $365.00 to $550.00. On average, they predict the company's stock price to reach $461.00 in the next year. This suggests a possible upside of 58.8% from the stock's current price.
View analysts price targets for BIO
or view top-rated stocks among Wall Street analysts.

How have BIO shares performed in 2024?

Bio-Rad Laboratories' stock was trading at $322.89 at the start of the year. Since then, BIO stock has decreased by 10.1% and is now trading at $290.25.
View the best growth stocks for 2024 here

Are investors shorting Bio-Rad Laboratories?

Bio-Rad Laboratories saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 733,100 shares, an increase of 6.5% from the April 15th total of 688,500 shares. Based on an average trading volume of 213,800 shares, the short-interest ratio is presently 3.4 days. Approximately 3.7% of the shares of the stock are sold short.
View Bio-Rad Laboratories' Short Interest

When is Bio-Rad Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our BIO earnings forecast

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) released its earnings results on Tuesday, May, 7th. The medical research company reported $2.29 EPS for the quarter, topping analysts' consensus estimates of $2.04 by $0.25. The medical research company earned $610.82 million during the quarter, compared to analyst estimates of $619.09 million. Bio-Rad Laboratories had a negative net margin of 12.37% and a positive trailing twelve-month return on equity of 3.59%. The firm's quarterly revenue was down 9.8% compared to the same quarter last year. During the same period in the prior year, the company earned $3.34 EPS.
Read the conference call transcript

What guidance has Bio-Rad Laboratories issued on next quarter's earnings?

Bio-Rad Laboratories issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.7 billion-$2.7 billion, compared to the consensus revenue estimate of $2.7 billion.

What is Norman Schwartz's approval rating as Bio-Rad Laboratories' CEO?

325 employees have rated Bio-Rad Laboratories Chief Executive Officer Norman Schwartz on Norman Schwartz has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), NVIDIA (NVDA), Broadcom (AVGO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Intel (INTC).

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.49%), Earnest Partners LLC (1.81%), Westfield Capital Management Co. LP (0.81%), Sei Investments Co. (0.65%), Allspring Global Investments Holdings LLC (0.57%) and Allspring Global Investments Holdings LLC (0.57%). Insiders that own company stock include Ajit Ramalingam, Annette Tumolo, Dara Wright, Ilan Daskal, Michael Crowley, Timothy S Ernst and Timothy S Ernst.
View institutional ownership trends

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Bio-Rad Laboratories have any subsidiaries?
The following companies are subsidiares of Bio-Rad Laboratories: (f/k/a Bio-Rad Laboratories (Israel) Inc.), BIO-RAD spol. s r.o., Bio-Metrics (U.K.) Limited, Bio-Rad, Bio-Rad (Shanghai) Life Science Research & Development Co. Ltd., Bio-Rad 1, Bio-Rad AbD Serotec GmbH, Bio-Rad AbD Serotec Ltd, Bio-Rad China Ltd., Bio-Rad Denmark ApS, Bio-Rad Europe GmbH, Bio-Rad Export LLC, Bio-Rad Finland Oy (f/k/a DiaMed Fennica Oy), Bio-Rad France, Bio-Rad France Holding, Bio-Rad Germany Holding GmbH, Bio-Rad Haifa Ltd., Bio-Rad Holdings LLC, Bio-Rad Hungary Trading LLC, Bio-Rad IHC Europe GmbH, Bio-Rad Innovations, Bio-Rad Korea Ltd., Bio-Rad Laboratories (Canada) Limited, Bio-Rad Laboratories (India) Private Limited, Bio-Rad Laboratories (Pty) Ltd, Bio-Rad Laboratories (Rishon) Inc., Bio-Rad Laboratories (Shanghai) Co. Ltd., Bio-Rad Laboratories (Singapore) Pte Ltd, Bio-Rad Laboratories AB, Bio-Rad Laboratories AG, Bio-Rad Laboratories B.V., Bio-Rad Laboratories Ges.m.b.H., Bio-Rad Laboratories GmbH, Bio-Rad Laboratories K.K., Bio-Rad Laboratories Limited, Bio-Rad Laboratories Logistik GmbH, Bio-Rad Laboratories Ltd., Bio-Rad Laboratories M.EPE, Bio-Rad Laboratories NV, Bio-Rad Laboratories Pty Ltd, Bio-Rad Laboratories S.A., Bio-Rad Laboratories S.r.l., Bio-Rad Laboratories SAS, Bio-Rad Laboratories-Aparelhos e Reagentes para Laboratórios Lda, Bio-Rad Laboratorii OOO, Bio-Rad Laboratórios Brasil Ltda., Bio-Rad Luxembourg S.à r.l., Bio-Rad Medical Diagnostics GmbH, Bio-Rad Middle East FZ-LLC, Bio-Rad Norway AS, Bio-Rad Pacific Limited, Bio-Rad Pasteur, Bio-Rad Polska Sp. z o.o., Bio-Rad QL Inc., Bio-Rad S.A., Bio-Rad Services France, Bio-Rad Services UK Limited, Biotest - Businesses, Blackhawk Biosystems, Bridger Technologies Inc., Celsee, Ciphergen Biosystems - ProteinChip Systems Business, DiaMed (G.B.) Ltd, DiaMed (Schweiz) GmbH, DiaMed Benelux NV, DiaMed Diagnostika Deutschland GmbH, DiaMed France SA, DiaMed GmbH, DiaMed Holding AG, DiaMed Holding GmbH, DiaMed Latino-América S.A., DiaMed S.E.A. Limited, DiaMed Österreich GmbH, Distribudora de Analítica para la Medicina Ibérica S.A.U., Dropworks Inc., GnuBIO Inc., Helix Diagnostics, IMV Medical Information Division Inc., International Marketing Ventures Ltd., MJ GeneWorks, Propel Labs - Cell Sorting System Division, QuantaLife, Quantase Ltd., Raindance Technologies Limited, Raindance Techologies Inc., Research Specialties for Laboratories NV, Respiratory Diagnostics Inc., and Wuxi BioCanal Nano Technology Co. Ltd..
Read More
This page (NYSE:BIO) was last updated on 5/24/2024 by Staff

From Our Partners